Pfizer CEO awarded 2,883 phantom stock units

Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of derivative securities linked to Pfizer common stock.

Rhea-AI Filing Summary

Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of derivative securities linked to Pfizer common stock. On 02/12/2026, he received 2,883 Phantom Stock Units SSP at $27.47 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Each unit represents one phantom share of common stock and is settled in cash after his separation from service. Following this grant, Bourla beneficially owned 757,286 derivative units on a direct basis, providing additional deferred, cash-settled exposure to Pfizer’s share value rather than immediate stock ownership.

Insider Trade Summary

Grant/Award: 2,883 shares

Grant/Award 1 txn

Insider BOURLA ALBERT

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units SSP	2,883	$27.47	$79K

Holdings After Transaction: Phantom Stock Units SSP — 757,286 contracts (Direct)

Footnotes (2)

1. F1. Each unit represents one phantom share of common stock.
2. F2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pfizer (PFE) report for Albert Bourla on February 12, 2026?

Albert Bourla reported acquiring 2,883 Phantom Stock Units SSP on February 12, 2026. These derivative units track Pfizer common stock and were granted under a company deferred compensation plan, increasing his directly held phantom units to 757,286 after the transaction.

What are the Phantom Stock Units SSP reported by Pfizer (PFE) for Albert Bourla?

The Phantom Stock Units SSP each represent one phantom share of Pfizer common stock. They are bookkeeping units granted under a nonfunded deferred compensation and supplemental savings plan and are settled in cash rather than stock, based on Pfizer’s share value at settlement.

How and when are Albert Bourla’s Pfizer (PFE) phantom stock units settled?

Albert Bourla’s phantom stock units are settled in cash after his separation from service. The cash value is tied to Pfizer’s common stock, and the plan allows him to move these units into an alternative investment account at any time before settlement.

How many Pfizer (PFE) phantom stock units does Albert Bourla hold after this Form 4?

After the February 12, 2026 grant, Albert Bourla beneficially owns 757,286 phantom stock units. This total reflects the newly acquired 2,883 units and represents his directly held derivative interest linked to Pfizer common stock through the deferred compensation plan.

Does Albert Bourla’s Pfizer (PFE) phantom stock grant involve direct share ownership?

The reported grant does not involve direct share ownership; it involves phantom stock units settled in cash. Each unit tracks one Pfizer common share’s value, providing economic exposure without issuing actual shares until cash settlement after his separation from service.

Under which plan were Albert Bourla’s new Pfizer (PFE) phantom stock units granted?

The 2,883 phantom stock units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. This plan grants cash-settled phantom units and permits the reporting person to transfer them into an alternative investment account at any time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 05:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOURLA ALBERT

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units SSP	(1)	02/12/2026		A		2,883		(2)	(2)	Common Stock	2,883	$27.47	757,286	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

	/s/ Shanice A. Reid, by power of atty., for Albert Bourla	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.